样本编号	SAMC3768861
外部数据库编号	GSA-Human: HRS1256976
样品名称	Sample1 of D15
样本标题	cfDNA
样品类型	Human sample
物种名称	Homo sapiens
描述信息	cfDNA sample
样本属性	*该样本包含更多受控访问信息，请通过GSA-Human系统申请项目HRA007484数据获取。
发布日期	2025-05-03
项目编号	PRJCA026407
提交者	Xiaodong Cheng (chengxd@zju.edu.cn)
提交单位	Zhejiang University
提交日期	2024-05-31

样本包含数据信息

资源名称	描述
GSA-Human (1)	-
HRA007484 (Controlled Access)	We evaluated the feasibility and efficacy of a multi-analyte approach combining circulating tumor DNA (ctDNA) detection with protein biomarkers for early OC detection. At 95% specificity, predictive models using CA125 and ctDNA alone exhibited an overall sensitivity of 79.0% and 58.7%, respectively; however, when CA125 was combined with ctDNA, sensitivity reached 85.5%. Integrating CA125 and HE4 in the Risk of Ovarian Malignancy Algorithm (ROMA) index, yielded a sensitivity of 86.2%. When four additional proteins were added to CA125 and ctDNA in the EarlySEEK model, sensitivity increased to 94.2%. In patients with early-stage epithelial OC, CA125 alone yielded a sensitivity of 63.5%, whereas the sensitivities of the CA125+ctDNA, ROMA, and EarlySEEK models were 73.1%, 76.9%, and 90.4%, respectively. EarlySEEK was not affected by menopausal status, and outperformed CA125 and ROMA in distinguishing benign and malignant ovarian tumors in post-menopausal populations.

资源名称

描述

GSA-Human (1)

HRA007484 (Controlled Access)

We evaluated the feasibility and efficacy of a multi-analyte approach combining circulating tumor DNA (ctDNA) detection with protein biomarkers for early OC detection. At 95% specificity, predictive models using CA125 and ctDNA alone exhibited an overall sensitivity of 79.0% and 58.7%, respectively; however, when CA125 was combined with ctDNA, sensitivity reached 85.5%. Integrating CA125 and HE4 in the Risk of Ovarian Malignancy Algorithm (ROMA) index, yielded a sensitivity of 86.2%. When four additional proteins were added to CA125 and ctDNA in the EarlySEEK model, sensitivity increased to 94.2%. In patients with early-stage epithelial OC, CA125 alone yielded a sensitivity of 63.5%, whereas the sensitivities of the CA125+ctDNA, ROMA, and EarlySEEK models were 73.1%, 76.9%, and 90.4%, respectively. EarlySEEK was not affected by menopausal status, and outperformed CA125 and ROMA in distinguishing benign and malignant ovarian tumors in post-menopausal populations.